Literature DB >> 4053456

Gliomatosis cerebri: clinical and histological findings.

J Artigas, J Cervos-Navarro, J R Iglesias, G Ebhardt.   

Abstract

The clinical and pathological data of ten patients with gliomatosis cerebri are compared with 48 well documented cases from the literature. The most striking clinical findings were behavioural and mental changes, seizures, motor weakness and headaches. Though diagnostic techniques have gained in sophistication, the clinical diagnosis of gliomatosis cerebri remains difficult. Laboratory and radiograph tests are mostly unconclusive. Expectations that computed tomography might lead to an accurate diagnosis were not fulfilled. Histological examination disclosed a diffuse proliferation of glial elements infiltrating normal nervous tissue with destruction of myelin sheaths, but only slight damage to neurons and axons. In two cases, areas typical of oligodendroglioma were also present. Glial fibrillary acidic protein staining showed in seven cases that most of the neoplastic cells were of astrocytic origin. In addition, GFAP negative neoplastic cells with the appearance of oligodendroglia and intermediate elements between astroglia and oligodendroglia and irregularly shaped naked nuclei of unidentified nature were found. On the basis of the two-stage theory of carcinogenesis, it is suggested that this disease might be the result of propagation of initiated glial elements which have not yet undergone the process of tumor conversion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4053456

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  33 in total

1.  Progressive dementia and gait disorder in a 78 year old woman.

Authors:  M Tagliati; D P Perl; B Drayer; C W Olanow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-04       Impact factor: 10.154

2.  Assessment of proliferative potential in gliomatosis cerebri.

Authors:  A Hara; N Sakai; H Yamada; T Tanaka; H Mori
Journal:  J Neurol       Date:  1991-04       Impact factor: 4.849

3.  Gliomatosis cerebri: post-mortem molecular and immunohistochemical analyses in a case treated with thalidomide.

Authors:  C Mawrin; V Aumann; E Kirches; R Schneider-Stock; C Scherlach; S Vogel; U Mittler; K Dietzmann; G Krause; S Weis
Journal:  J Neurooncol       Date:  2001-10       Impact factor: 4.130

4.  Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.

Authors:  Sophie Taillibert; Catherine Chodkiewicz; Florence Laigle-Donadey; Massimo Napolitano; Stéphanie Cartalat-Carel; Marc Sanson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

5.  The fine structure of gliomatosis cerebri.

Authors:  J Cervos-Navarro; J Artigas; C Aruffo; J Iglesias
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1987

6.  Dynamic contrast-enhanced T2*-weighted MR imaging of gliomatosis cerebri.

Authors:  Stanley Yang; Stephan Wetzel; M Law; D Zagzag; Soonmee Cha
Journal:  AJNR Am J Neuroradiol       Date:  2002-03       Impact factor: 3.825

7.  Diffuse cerebrospinal gliomatosis presenting as motor neuron disease for two years.

Authors:  M Schmidbauer; C Müller; I Podreka; B Mamoli; E Sluga; L Deecke
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-02       Impact factor: 10.154

8.  Histological and MR correlations in Gliomatosis cerebri.

Authors:  Paule Peretti-Viton; Hervé Brunel; Olivier Chinot; Clément Daniel; Maryline Barrié; Corinne Bouvier; Dominique Figarella-Branger; Stéphane Fuentes; Henry Dufour; François Grisoli
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  Impact of adjuvant chemotherapy for gliomatosis cerebri.

Authors:  Doo-Sik Kong; Sung Tae Kim; Jung-Il Lee; Yeon-Lim Suh; Do Hoon Lim; Won Seog Kim; Ki-Hoon Kwon; Kwan Park; Jong Hyun Kim; Do-Hyun Nam
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

10.  Gliomatosis cerebri: report of a case presenting as a focal cerebral mass.

Authors:  N W Wilson; L Symon; P L Lantos
Journal:  J Neurol       Date:  1987-08       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.